BioInvent International AB logo

BINV - BioInvent International AB Share Price

SEK52 0.9  1.7%

Last Trade - 26/02/21

Sector
Healthcare
Size
Small Cap
Market Cap £174.3m
Enterprise Value £113.2m
Revenue £12.5m
Position in Universe 739th / 1874
Bullish
Bearish
Unlock BINV Revenue
Momentum
Relative Strength (%)
1m -10.3%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -17.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
15.9 71.3 45.0 38.5 93.7 147.4 307 40.0 +56.1%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020,BioInvent International AB revenues increased 57% toSEK147.4M. Net loss decreased 45% to SEK76.3M. Revenuesreflect an increase in demand for the Company's productsand services due to favorable market conditions. BasicEarnings per Share excluding Extraordinary Items increasedfrom -SEK7.51 to -SEK2.66.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BINV Revenue Unlock BINV Revenue

Net Income

BINV Net Income Unlock BINV Revenue

Normalised EPS

BINV Normalised EPS Unlock BINV Revenue

PE Ratio Range

BINV PE Ratio Range Unlock BINV Revenue

Dividend Yield Range

BINV Dividend Yield Range Unlock BINV Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BINV EPS Forecasts Unlock BINV Revenue
Profile Summary

BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Public Since June 12, 2001
No. of Shareholders: n/a
No. of Employees: 73
Sector Healthcare
Industry Biotechnology & Medical Research
Index
Exchange OMX Nordic Exchange Stockholm
Shares in Issue 39,376,000
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BINV Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BINV
Upcoming Events for BINV
Frequently Asked Questions for BioInvent International AB
What is the BioInvent International AB share price?

As of 26/02/21, shares in BioInvent International AB are trading at SEK52, giving the company a market capitalisation of £174.3m. This share price information is delayed by 15 minutes.

How has the BioInvent International AB share price performed this year?

Shares in BioInvent International AB are currently trading at SEK52 and the price has moved by 60.39% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the BioInvent International AB price has moved by 48.15% over the past year.

What are the analyst and broker recommendations for BioInvent International AB?

Of the analysts with advisory recommendations for BioInvent International AB, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for BioInvent International AB is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will BioInvent International AB next release its financial results?

BioInvent International AB is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the BioInvent International AB dividend yield?

BioInvent International AB does not currently pay a dividend.

Does BioInvent International AB pay a dividend?

BioInvent International AB does not currently pay a dividend.

When does BioInvent International AB next pay dividends?

BioInvent International AB does not currently pay a dividend.

How do I buy BioInvent International AB shares?

To buy shares in BioInvent International AB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of BioInvent International AB?

Shares in BioInvent International AB are currently trading at SEK52, giving the company a market capitalisation of £174.3m.

Where are BioInvent International AB shares listed? Where are BioInvent International AB shares listed?

Here are the trading details for BioInvent International AB:

Country of listing: Sweden
Exchange: STO
Ticker Symbol: BINV
What kind of share is BioInvent International AB?

Based on an overall assessment of its quality, value and momentum, BioInvent International AB is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a BioInvent International AB share price forecast 2021?

Shares in BioInvent International AB are currently priced at SEK52. At that level they are trading at 34.62% discount to the analyst consensus target price of 0.00.

Analysts covering BioInvent International AB currently have a consensus Earnings Per Share (EPS) forecast of 15.965 for the next financial year.

How can I tell whether the BioInvent International AB share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BioInvent International AB. Over the past six months, the relative strength of its shares against the market has been 20.15%. At the current price of SEK52, shares in BioInvent International AB are trading at 21.21% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the BioInvent International AB PE Ratio?

We were not able to find PE ratio data for BioInvent International AB.

Who are the key directors of BioInvent International AB?

BioInvent International AB's management team is headed by:

Stefan Ericsson - CFO
Bjorn Frendeus - CSO
Dharminder Chahal - IND
Vessela Alexieva - DRC
Leonard Kruimer - CHM
Vincent Ossipow - IND
Kristoffer Rudenholm Hansson - SVP
Elin Jaensson Gyllenback - DRC
Martin Welschof - PRE
Bernd Seizinger - IND
Andres McAllister - OTH
Who are the major shareholders of BioInvent International AB?

Here are the top five shareholders of BioInvent International AB based on the size of their shareholding:

van Herk (Adrianus) Individual Investor
Percentage owned: 12.26% (5.17m shares)
Omega Fund Management, LLC Investment Advisor
Percentage owned: 9.83% (4.15m shares)
HBM Partners AG Investment Advisor
Percentage owned: 5.49% (2.32m shares)
Fjärde AP-Fonden Pension Fund
Percentage owned: 5.3% (2.24m shares)
Compagnie Mérieux Alliance Holding Company
Percentage owned: 3.59% (1.52m shares)
Similar to BINV
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.